# A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients

> **NCT00592475** · PHASE2 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** conivaptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00592475
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00592475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00592475, "A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00592475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*